Published in Clin Transplant on June 30, 2013
Post-transplant malignancy in liver transplantation: a single center experience. Medicine (Baltimore) (2014) 1.44
Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant (2014) 0.94
Melanoma Risk and Survival among Organ Transplant Recipients. J Invest Dermatol (2015) 0.85
Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol (2016) 0.78
De novo cancers following liver transplantation: a single center experience in China. PLoS One (2014) 0.77
Female gender in the setting of liver transplantation. World J Transplant (2014) 0.77
Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol (2015) 0.76
Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years' Experience. Eurasian J Med (2016) 0.75
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management. World J Gastroenterol (2016) 0.75
Betel quid chewing leads to the development of unique de novo malignancies in liver transplant recipients, a retrospective single center study in Taiwan. Medicine (Baltimore) (2016) 0.75
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl (2002) 2.00
Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl (2008) 1.97
Epidemiology of alcoholic liver disease. Semin Liver Dis (1988) 1.96
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94
Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation (1972) 1.80
Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl (2008) 1.78
Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64
Risk factors for cancer in renal transplant recipients. Transplantation (1999) 1.54
Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40
Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant (2007) 1.37
Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28
The problem of cancer in organ transplant recipients: an overview. Transplant Sci (1994) 1.22
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ (2010) 1.18
Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology (2009) 1.18
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13
Chronic antigenic stimulation, herpesvirus infection, and cancer in transplant recipients. Lancet (1975) 1.09
De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant (2004) 1.09
De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07
Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation (2005) 1.05
Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis (2009) 1.01
De novo tumors after liver transplantation: a single-institution experience. Liver Transpl (2002) 1.00
Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol (2007) 0.99
Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl (2001) 0.98
Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant (2009) 0.93
Bronchogenic carcinoma in solid organ transplant recipients. Curr Treat Options Oncol (2006) 0.92
Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc (1999) 0.89
Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl (2008) 0.88
Liver transplantation trends for older recipients: regional and ethnic variations. Transplantation (2008) 0.88
Alcohol abuse and de novo tumors in liver transplantation. Transplant Proc (2009) 0.85
Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl (2004) 0.85
Upper aerodigestive tract and lung tumors after liver transplantation. Transplant Proc (2003) 0.82
Recurrent nonhepatic and de novo malignancies after liver transplantation. Transplantation (2009) 0.81
Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci (1994) 0.80
[Incidence of de novo neoplasms after liver transplantation]. Med Clin (Barc) (1998) 0.77
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology (2014) 4.04
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Performance of high flow rate samplers for respirable particle collection. Ann Occup Hyg (2010) 3.16
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Predictors of nonadherence to screening colonoscopy. J Gen Intern Med (2005) 2.80
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation (2014) 2.00
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol (2009) 1.98
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.80
Comparison of probe-based confocal laser endomicroscopy with virtual chromoendoscopy for classification of colon polyps. Gastroenterology (2009) 1.80
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Double knockout pigs deficient in N-glycolylneuraminic acid and galactose α-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation (2013) 1.72
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Multivisceral transplantation for diffuse portomesenteric thrombosis. Ann Surg (2012) 1.64
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and University of Wisconsin solution (UW) in adult liver transplantation. Liver Transpl (2006) 1.57
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Hexavalent chromium content in stainless steel welding fumes is dependent on the welding process and shield gas type. J Environ Monit (2008) 1.50
Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl (2008) 1.49
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Estimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repair. J Vasc Surg (2012) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Efficient selection of Gal-knockout pig cells for somatic cell nuclear transfer. J Surg Res (2012) 1.41
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Immunogenicity of Renal Microvascular Endothelial Cells From Genetically Modified Pigs. Transplantation (2016) 1.38
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Epidemiology of acute liver failure. Curr Gastroenterol Rep (2007) 1.27
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer (2011) 1.18
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Current status of small bowel and multivisceral transplantation. Adv Surg (2008) 1.17
Clinical lung xenotransplantation--what donor genetic modifications may be necessary? Xenotransplantation (2012) 1.16
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol (2002) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med (2008) 1.11
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
Trainee participation is associated with increased small adenoma detection. Gastrointest Endosc (2011) 1.08
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Biallelic knockout of the α-1,3 galactosyltransferase gene in porcine liver-derived cells using zinc finger nucleases. J Surg Res (2012) 1.04
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology (2002) 1.02
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection. Xenotransplantation (2014) 1.01